This role is confirmed by the fact that inhibitors of the type 1 G protein-coupled receptor (GPCR) for cys-LTs (CysLT1R) [7], [8] and inhibitors of cys-LT synthesis [9] are clinically efficacious for the treatment of asthma. The gene discussed is CYSLTR1; the disease is asthma.